Alembic Pharmaceuticals logo

Alembic Pharmaceuticals financials and balance sheet

NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap

Last close ₹760.10down ₹21.20 (2.71%)BSE ₹758.75

Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.

52-week range of traded prices to 23 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
Market cap
₹14,941 Cr430th largest listed
P/E
21.6
P/B
2.6
Dividend yield
1.58%
ROE
12.7%
ROCE
11.8%
Debt to equity
0.24
Volume, NSE
1,20,84752.2% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Alembic Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.2% of operating profit in the first full year.

The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue7,345
  2. Materials and goods−1,984
  3. Employee costs−1,732
  4. Other expenses−2,510
  5. Operating profit1,118
  6. Depreciation−319
  7. Other income+54
  8. One-off items−67
  9. Finance costs−94
  10. Profit before tax694
  11. Tax−23
  12. Joint ventures+0.2
  13. Net profit671

What the company owns

  • Plant, investments and other assets₹4,583 Cr
  • Inventory₹2,511 Cr
  • Receivables₹1,466 Cr
  • Cash and bank₹203 Cr

What pays for it: net worth and liabilities

  • Net worth₹5,669 Cr
  • Borrowings₹1,361 Cr
  • Other liabilities₹898 Cr
  • Owed to suppliers₹835 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Alembic Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 9 MayMar 2020Filed 22 MayMar 2021Filed 5 MayMar 2022Filed 4 MayMar 2023Filed 6 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 15 May
Revenue from operations3,1353,1313,9354,6065,3935,3065,6536,2296,6727,345
2,5202,4883,0613,3833,8364,4324,9445,2955,6646,226
Materials and goods bought8588869931,0391,2571,4461,7091,7151,7931,984
Employee costs–6237479061,0511,1331,1691,4461,5621,732
Other expenses–9791,3221,4371,5271,8522,0662,1342,3082,510
Operating profit before depreciation6156438741,2231,5588747089331,0081,118
Operating margin19.6%20.5%22.2%26.6%28.9%16.5%12.5%15.0%15.1%15.2%
Materials, % of revenue–28.3%25.2%22.6%23.3%27.3%30.2%27.5%26.9%27.0%
Employee costs, % of revenue–19.9%19.0%19.7%19.5%21.4%20.7%23.2%23.4%23.6%
Other expenses, % of revenue–31.3%33.6%31.2%28.3%34.9%36.6%34.3%34.6%34.2%
Depreciation and amortisation83105115157183287275273279319
Operating profit after depreciation5325387581,0661,374587433661730800
Other income279510503284354
Finance costs531827161850567994
Profit before one-off items and tax5295417491,0431,368620386633693761
One-off items000−44000013−67
Profit before tax5295417491,0001,368620386633706694
122120157199253104131612523
Share of profit of joint ventures and associates−4−8−90325−31−110
4034135838011,147521342616582671
Other comprehensive income––6−2−4113−11625
Total comprehensive income––5897991,143522355605588696
Net margin12.9%13.2%14.8%17.4%21.3%9.8%6.1%9.9%8.7%9.1%
Net margin without joint ventures and associates13.0%13.4%15.1%17.4%20.7%9.7%6.6%9.9%8.7%9.1%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2017 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 9 MayMar 2020Filed 22 MayMar 2021Filed 5 MayMar 2022Filed 4 MayMar 2023Filed 6 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 15 May
2,7183,1905,0675,2384,3704,8185,1905,669
2,7193,2195,1285,2384,3704,8185,1915,675
Share capital3838393939393939
Reserves2,6813,1825,0885,1984,3314,7795,1525,636
Belonging to outside owners of subsidiaries−1−29−61000−1−6
9281,7472006306364301,1961,361
1,4901,7521,2811,7171,6371,4552,4122,594
5701,047361168175172171500
4,7785,9896,7097,1226,1836,4467,7738,763
2,8203,5264,1314,3433,2733,3673,6854,190
1,9582,4632,5782,7792,9103,0794,0884,543
Net debt7231,667−935615543041,1051,158
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 5 MayMar 2022Filed 4 MayMar 2023Filed 6 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 15 May
1,46355272480388783
1,709676785823159886
240−367−58−96−643−257
Receivables511−470−22339−3958
Inventories−299−124134−168−645−223
Payables4537−2856146−49
Other working capital−1818959−222517
Tax paid−245−123−61−20−71−104
Capital spending660426443327564435
Free cash flow804127281476−476348
−839−372−448−321−568−506
−597−217−262−438444−164
Dividends paid0275197157216216
Shares bought back000000
Shares issued73400000
Net change in cash27−371445−37113
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Alembic Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 9 MayMar 2020Filed 22 MayMar 2021Filed 5 MayMar 2022Filed 4 MayMar 2023Filed 6 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 15 May
Earnings per share₹21.39₹21.89₹31.00₹43.97₹60.81₹27.76₹17.40₹31.33₹29.68₹34.33
Diluted earnings per share₹21.39₹21.89₹31.00₹43.97₹60.81₹27.76₹17.40₹31.33₹29.68₹34.33
Dividend per share₹4.00₹4.00₹5.50₹10.00₹14.00–₹18.00₹11.00₹11.00₹12.00
Book value per share––₹144.23₹170.78₹260.86₹266.45₹222.34₹245.12₹264.10₹288.72
Dividend payout18.7%18.3%17.7%22.7%23.4%–103.5%35.1%37.1%35.4%
Shareholder yield––––−3.9%1.9%2.0%0.8%1.2%1.7%
Market cap at the year end (₹ crore)11,82810,33710,13810,07118,96714,5779,75619,35818,27513,037

Ratios

Consolidated, years to March.Alembic Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 9 MayMar 2020Filed 22 MayMar 2021Filed 5 MayMar 2022Filed 4 MayMar 2023Filed 6 MayMar 2024Filed 10 MayMar 2025Filed 10 JunMar 2026Filed 15 May
Revenue growth−0.4%––17.1%17.1%−1.6%6.5%10.2%7.1%10.1%
Operating profit growth−38.9%4.6%35.8%40.0%27.4%−43.9%−19.0%31.8%8.0%10.9%
Net profit growth−44.0%2.3%41.4%37.3%43.2%−54.6%−34.4%80.1%−5.5%15.3%
Earnings per share growth–2.3%41.6%41.8%38.3%−54.3%−37.3%80.1%−5.3%15.7%
––21.5%27.9%28.2%10.5%7.1%13.4%11.7%12.3%
–––6.4 pts0.3 pts−17.7 pts−3.4 pts6.3 pts−1.7 pts0.6 pts
From the net margin–––4.5 pts6.0 pts−14.9 pts−4.3 pts4.5 pts−1.5 pts0.4 pts
From asset turnover–––1.0 pts−0.2 pts−1.3 pts0.7 pts1.9 pts−0.6 pts−0.6 pts
From borrowing–––0.9 pts−5.4 pts−1.5 pts0.3 pts−0.1 pts0.4 pts0.8 pts
Return on capital employed––20.8%21.6%26.1%10.0%8.6%12.6%11.4%11.4%
Cash conversion––––127.6%106.0%211.7%130.4%15.1%116.7%
Interest cover103.9158.141.239.285.833.18.611.89.38.5
Debt to equity––0.340.550.040.120.150.090.230.24
Receivable days––4569245668607773
Inventory days––356417431406315350466462
Payable days––258220194178145157179154
Cash conversion cycle, days––143266261283237253363381
Working capital days––6411868112118113152148
Asset turnover––0.820.860.850.770.850.990.940.89
Assets per rupee of net worth––1.761.811.521.331.381.371.421.52
Sales per rupee of plant––3.583.023.173.052.362.452.642.58
Capital spending to depreciation––––3.591.481.611.202.021.36
Plant being built, % of plant in use––122.1%103.2%114.1%126.6%25.1%20.6%33.2%22.3%
Revenue growth is left blank for the years to Mar 2018 and Mar 2019: between the two periods excise duty was taken out of revenue when GST replaced it, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.1%
Cash from operations against operating profit
70.0%
Measure10 years5 years3 years
Revenue growth, yearly rate8.8%6.4%9.1%
Profit growth, yearly rate−0.8%−10.8%24.9%
Return on equity, average–11.0%12.4%
Return on capital employed, average–10.8%11.8%
Operating margin, average19.2%14.9%15.1%
Net margin, average12.3%8.7%9.2%
Asset turnover, average–0.890.94
Cash conversion cycle, days, average–304333
Interest cover, average49.914.39.9
Debt to equity, average–0.170.19

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations2,9501,674783
Cash from investing−2,215−1,395−506
Cash from financing−637−158−164
Capital spending2,1951,326435
Dividends paid1,061590216
Shares bought back000
Shares issued for cash000
Borrowings raised1,566930165
Borrowings repaid7052050

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––656855
Altman Z-scorePublished threshold 1.81––5.214.389.716.885.609.806.624.83
Beneish M-scorePublished threshold −1.78––––−2.93−1.48−2.72−2.61−2.00−2.46
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––8.224.930.992.1114.944.77
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.361.411.050.90
Receivables growth less revenue growthOur threshold 0 percentage points–––59.83−76.79133.1723.11−12.2529.47−5.33
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––18.074.18−6.73−26.4911.0434.66−0.93
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.732.24−2.960.23−0.360.390.72
Assets under construction, years of additionsOur threshold 2 years of additions–––2.705.376.780.651.253.280.99
Effective tax ratePublished threshold 17.16 per cent23.0922.2320.9219.9218.5216.843.272.5317.723.33
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−3.06−12.48−0.617.61−11.62
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
30 Jun 2026CRISIL Ratings Limited (opens in a new tab)Commercial PaperCrisil A1+Review, Re-affirm1,100
30 Jun 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil AA+Review, Re-affirmStable500
11 Jun 2026CARE Ratings Limited (opens in a new tab)Commercial PaperShort-term scaleCARE A1+Review, Re-affirmISINs INE901L14BH4, INE901L14BI2, INE901L14BJ0, INE901L14BK8, INE901L14BL6 redeemed.150
11 Jun 2026CARE Ratings Limited (opens in a new tab)Commercial PaperShort-term scaleCARE A1+Review, Re-affirmProposed, ISINs INE901L14BH4, INE901L14BI2, INE901L14BJ0, INE901L14BK8, INE901L14BL6 redeemed.950
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.